Increased cholesterol decreases uterine activity: functional effects of cholesterol alteration in pregnant rat myometrium.
Uterine quiescence is essential for successful pregnancy. Cholesterol and triglycerides are markedly increased in pregnancy. Cholesterol is enriched in microdomains of the plasma membrane known as rafts and caveolae. Both lipid rafts and caveolae have been implicated in cellular signaling cascades. The purpose of this work was to investigate whether manipulation of cholesterol content alters uterine contractility. Late pregnancy (19-21 days) rats were humanely euthanized and strips of longitudinal myometrium were then dissected. Force and Ca(2+) measurements were simultaneously recorded and cholesterol increased by the addition of 5 mg/ml cholesterol or 0.25 mg/ml low-density lipoproteins (LDLs) or reduced by 2% methyl-beta-cyclodextrin (MCD) or 2 U/ml cholesterol oxidase addition to the perfusate. Both LDLs and cholesterol profoundly inhibited spontaneous uterine force production and associated Ca(2+) transients; frequency, amplitude, and duration of contraction were all significantly reduced compared with preceding control contractions. Force and Ca(2+) were also reduced by cholesterol when 1 nM oxytocin was used to stimulate the myometrium. Uterine activity was significantly increased by cholesterol extraction with MCD or cholesterol oxidase treatment. Electron microscopy confirmed the lipid raft disrupting effect of MCD, as formerly electron microscopy-visible caveolae in the myometrial cell membrane all but disappeared after MCD treatment. These data show that uterine smooth muscle cell cholesterol content is critically important for functional activity. A novel finding of our study is that cholesterol is inhibitory for force generation. It may be one of the mechanisms operating to maintain uterine quiescence throughout gestation and may also contribute to difficulties in labor suffered by obese women.
Smith
R D
RD
Dept. of Physiology, The University of Liverpool, Crown St., Liverpool, L69 3BX, UK. dsmith@liv.ac.uk
Babiychuk
E B
EB
Noble
K
K
Draeger
A
A
Wray
Susan
S
D000818:Animals; D002118:Calcium / Q000378:metabolism; D021941:Caveolae / Q000187:drug effects / Q000378:metabolism / Q000502:physiology / Q000648:ultrastructure; D002784:Cholesterol / Q000378:metabolism*; D002789:Cholesterol Oxidase / Q000494:pharmacology; D005260:Female; D066298:In Vitro Techniques; D008077:Lipoproteins, LDL / Q000494:pharmacology; D021962:Membrane Microdomains / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology / Q000648:ultrastructure; D046529:Microscopy, Electron, Transmission; D009215:Myometrium / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology / Q000648:ultrastructure; D010121:Oxytocin / Q000494:pharmacology; D011247:Pregnancy; D051381:Rats; D014590:Uterine Contraction / Q000187:drug effects / Q000502:physiology*; D014599:Uterus / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology / Q000648:ultrastructure; D047392:beta-Cyclodextrins / Q000494:pharmacology
D008077:Lipoproteins, LDL; D047392:beta-Cyclodextrins; C108732:methyl-beta-cyclodextrin; D010121:Oxytocin; D002784:Cholesterol; D002789:Cholesterol Oxidase; D002118:Calcium